Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CHAD THERAPEUTICS INC (CTU)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
10.2
|
M
| |
|
|
| Market cap: |
$27.4
|
k
| |
|
|
|
Net cash:
|
$683
|
k
| |
$0.07
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-08 | Mar-31-07 | Mar-31-06 | Mar-31-05 | Mar-31-04 | Mar-31-03 | Mar-31-02 | Mar-31-01 |
| Revenues | 0.0 | 0.0 | 22.4 | 24.3 | 21.5 | 19.5 | 19.0 | 12.4 |
| Revenue growth | | -100.0% | -8.0% | 12.7% | 10.2% | 2.8% | 53.3% | |
| Cost of goods sold | 0.0 | 0.0 | 15.1 | 14.6 | 12.8 | 12.3 | 11.8 | 9.7 |
| Gross profit | 0.0 | 0.0 | 7.2 | 9.7 | 8.7 | 7.2 | 7.2 | 2.7 |
| Gross margin | | | 32.4% | 40.0% | 40.4% | 37.1% | 37.7% | 21.8% |
| Selling, general and administrative | 2.3 | 2.5 | 6.8 | 6.9 | 6.4 | 6.7 | 6.2 | 5.1 |
| Research and development | 0.8 | 0.2 | 1.6 | 1.5 | 1.3 | 1.0 | 0.8 | 0.7 |
| EBITA | -6.0 | -2.7 | -1.1 | 1.3 | 1.0 | -0.4 | 0.1 | -3.1 |
| EBITA margin | | | -4.8% | 5.5% | 4.5% | -2.3% | 0.6% | -25.0% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | |
| EBIT | -6.0 | -2.8 | -1.1 | 1.3 | 1.0 | -0.4 | 0.1 | -3.1 |
| EBIT margin | | | -5.0% | 5.3% | 4.5% | -2.3% | 0.6% | -25.0% |
| Pre-tax income | -4.5 | -2.7 | -1.1 | 1.3 | 1.0 | -0.4 | 0.2 | -3.0 |
| Income taxes | 0.0 | 1.0 | -0.4 | -0.5 | 0.0 | 0.0 | -1.0 | 0.0 |
| Tax rate | | | 39.0% | | 0.0% | | | |
| Earnings from continuing ops | -4.5 | -3.7 | -0.7 | 1.8 | 1.0 | -0.4 | 1.2 | -3.0 |
| Earnings from discontinued ops | -3.6 | 0.3 | | | | | | |
| Net income | -8.6 | -3.4 | -0.7 | 1.8 | 1.0 | -0.4 | 1.2 | -3.0 |
| Net margin | | | -3.0% | 7.5% | 4.6% | -2.2% | 6.1% | -24.3% |
| |
| Diluted EPS | ($0.44) | ($0.36) | ($0.07) | $0.17 | $0.10 | ($0.04) | $0.11 | ($0.30) |
| Shares outstanding (diluted) | 10.2 | 10.2 | 10.1 | 10.6 | 10.4 | 10.1 | 10.4 | 10.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|